Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.
We are now publishing 4-5x per week according to the following cadence:
Mondays: BioBucks: Stock Analysis & Biotech Catalysts
Wednesdays: CRISPR Corner: Monthly gene editing news
Thursdays: Insiders Track: Public & Private Biotech Markets
Fridays: Sweat Equity: Your Weekly Biotech Fix
Sundays: Building Biotech: Strategic Topics
In addition we aim to put out 1-2 podcasts episodes per week. One on Tue/Wed focusing on interesting industry related content and a second on Fri/Sat which will likely be more of a news recap.
Please help spread the work by subscribing and hitting the share button if you are enjoying content!
Welcome to today’s episode of the Bowtied Biotech Podcast, where we explore the most compelling developments shaping the biotech and pharma landscape. In this episode, we delve into some headline-grabbing news: Marty Makary, a vocal critic of COVID-19 policies, emerges as Trump’s likely pick to lead the FDA, signaling potential shifts in regulatory priorities. We’ll also discuss Amgen’s strategic appointment of biotech pioneer Howard Chang as its new CSO, Pfizer’s C-Suite shake-up with Chris Boshoff taking the reins as CSO, and the latest groundbreaking deals, including Novartis’ acquisition of Kate Therapeutics to expand its gene therapy pipeline. From rare disease funding challenges to innovative approaches in obesity treatments, there’s no shortage of fascinating insights. Let’s break it all down!
📣🎙️ TODAY’S POCAST:
[ 0:00 ] Intro
[ 1:10 ] Pfizer and Amgen Leadership Shifts
[ 2:10 ] Acquisitions: Pfizer vs. Novartis Strategies
[ 3:19 ] Funding Challenges for Rare Disease Biotechs
[ 4:28 ] Regulatory Changes: Chevron Deference and FDA Implications
[ 5:16 ] The BioSecure Act and Domestic Manufacturing Push
[ 5:51 ] Obesity Treatments: Eli Lilly, Leichna, and MetSara Innovations
[ 6:55 ] Pricing Disparities: Wegovy in China vs. the U.S.
[ 7:43 ] Peptotango Therapeutics’ Multi-Target Obesity Drug
[ 8:12 ] Glycan-Targeting Immunotherapies by Valora Therapeutics
[ 9:06 ] Work Culture Shifts in Biopharma: Flexibility and Talent Retention
[ 10:32 ] Investment Landscape for Platform Biotechs
[ 12:10 ] Obesity: Treatment Innovations and Societal Benefits
[ 13:13 ] Ethical Challenges: Gene Editing, AI, and Access to Innovation
[ 14:41 ] Public Engagement in Biotech’s Future
[ 16:31 ] Balancing Innovation with Access and Responsibility
[ 17:34 ] Closing Thoughts: Key Takeaways and Future Topics
CONCLUSION
We hope you are enjoying our first leap into the podcast world! Instead of waiting until everything is perfect, we’re diving in and will continue improving as we go. Feel free to send us your suggestions, feedback, or constructive criticism—we’d love to hear from you!
As a reminder, if looking to go deeper into the topics we cover check out our website BowTiedBiotech.com, or DM us on twitter, or email us: bowtiedbiotech@gmail.com
ABOUT BOWTIEDBIOTECH
As a reminder, the purpose of the BowTiedBiotech substack is two-fold. Primarily, we aim to provide our scientist audience the tools to build a biotech company and ultimately translate their ideas into medicines for patients. Secondarily, biotech investors may find this substack useful as we will be providing weekly market updates of the public AND private markets as well as heavily leveraging current financing events as teaching examples.
DISCLAIMER
None of this is to be deemed legal or financial advice of any kind. All updates are sourced from publicly available disclosures. Insights are *opinions* written by an anonymous cartoon/scientist/investor.
TOP BOWTIEDBIOTECH NEWSLETTERS
Share this post